52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience F.J. Melgosa Ramos; A. Mateu Puchades; J. Matáix-Díaz; L. Schneller-Pavelescu; I. Belinchón-Romero; S. Santos Alarcón;

[Translated article] Practical Update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis With Biologic Therapy J.M. Carrascosa; L. Puig; I. Belinchón Romero; L. Salgado-Boquete; E. del Alcázar; J.J. Andrés Lencina; D. Moreno; P. de la Cueva;

Experiencia en la práctica clínica tras la optimización de la dosis del secukinumab en la psoriasis moderada-severa. Serie retrospectiva de 11 casos Á. Aguado Vázquez; F.J. Melgosa Ramos; C. Alonso Díez; A. Mateu Puchades;